OncoMatch/Clinical Trials/NCT06791083
Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
Is NCT06791083 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Envafolimab and Fruquintinib for gastric cancer.
Treatment: Envafolimab · Fruquintinib — To observe and evaluate the neoadjuvant treatment of Envafolimab combined with Fruquintinib and chemotherapy for locally advanced gastric/gastroesophageal junction carcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Gastric Cancer
Biomarker criteria
Excluded: HER2 (ERBB2) positive
Known HER2-positive patients
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: any systemic anti-tumor therapy
received other systemic anti-tumor therapy, including chemotherapy, signal transduction inhibitors, immunotherapy, and other investigational drugs within 4 weeks prior to enrollment
Cannot have received: investigational drug
Participated in other drug clinical trials and received at least one drug therapy within 4 weeks prior to enrollment
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×109/L; Platelet ≥80×109/L; Hemoglobin ≥90g/L
Kidney function
Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr)≥60ml/min; endogenous creatinine clearance > 50ml/min
Liver function
Total bilirubin < 1.5 ULN; ALT and AST < 2.5 ULN (< 5 ULN in patients with liver metastasis)
Cardiac function
NYHA heart function Grade ≤ II and left ventricular ejection fraction (LVEF) ≥ 50%
Absolute neutrophil count ≥1.5×109/L; Platelet ≥80×109/L; Hemoglobin ≥90g/L; Total bilirubin < 1.5 ULN; ALT and AST < 2.5 ULN (< 5 ULN in patients with liver metastasis); Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr)≥60ml/min; endogenous creatinine clearance > 50ml/min; NYHA heart function Grade > II or left ventricular ejection fraction (LVEF) < 50% [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06791083 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with ERBB2 alterations eligible?
No. ERBB2 positive is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages